Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Lopinavir (ABT-378): Potent HIV Protease Inhibitor for An...

    2025-11-06

    Lopinavir (ABT-378): Potent HIV Protease Inhibitor for Antiviral Research

    Executive Summary: Lopinavir (ABT-378) is a next-generation HIV protease inhibitor with inhibition constants (Ki) of 1.3–3.6 pM against both wild-type and mutant HIV proteases, outperforming ritonavir in serum stability and resistance avoidance [ApexBio]. Its EC50 is <0.06 μM in Val82 mutant strains, with a 10-fold greater potency in human serum compared to ritonavir. Oral administration at 10 mg/kg in animal models yields 0.8 μg/mL Cmax and 25% bioavailability, which increases 14-fold when co-administered with ritonavir. Lopinavir also exhibits low-micromolar activity against other viral pathogens, including coronaviruses, highlighting its cross-pathogen research value (de Wilde et al., 2014).

    Biological Rationale

    HIV protease is essential for the maturation of infectious HIV virions. Inhibiting this enzyme disrupts viral polyprotein processing, preventing the formation of mature, infectious viral particles [see molecular interplay]. Resistance mutations, such as Val82, can diminish the efficacy of first-generation inhibitors like ritonavir. Lopinavir, designed as a ritonavir analog, minimizes interaction at the Val82 residue, maintaining potency against resistant strains. Its enhanced performance in the presence of serum proteins directly addresses a key limitation of earlier inhibitors, supporting its central role in HIV infection research and antiretroviral therapy development [contrast: unmatched efficacy].

    Mechanism of Action of Lopinavir

    Lopinavir is a peptidomimetic HIV-1 protease inhibitor. It binds to the active site of the HIV protease enzyme, blocking cleavage of the Gag-Pol polyprotein precursor. This prevents the generation of mature viral core proteins and enzymes, leading to the production of non-infectious viral particles [comprehensive guide]. Lopinavir is structurally optimized for high-affinity binding, with reduced susceptibility to common resistance mutations. Unlike ritonavir, its antiviral activity is not significantly reduced by human serum proteins, allowing consistent inhibition in physiological conditions. The compound’s high selectivity and low nanomolar effective concentrations make it suitable for both wild-type and mutant HIV strains.

    Evidence & Benchmarks

    • Lopinavir inhibits both wild-type and mutant HIV proteases with Ki values of 1.3–3.6 pM under biochemical assay conditions (pH 5.0, 25°C) (ApexBio).
    • Against Val82 mutant HIV protease, Lopinavir maintains an EC50 <0.06 μM, demonstrating superior potency over ritonavir (ApexBio).
    • In the presence of 45% human serum, Lopinavir retains ~10-fold greater antiviral potency than ritonavir (cell-based assays, HIV-1 IIIB, 37°C, 48 h) (ApexBio).
    • Cell-based assays show effective inhibition at 4–52 nM concentrations (CEM cell line, HIV-1, 72 h) (ApexBio).
    • Oral dosing (10 mg/kg) in rodents yields Cmax 0.8 μg/mL, 25% bioavailability; plasma levels fall below quantitation by 6 h post-dose (ApexBio).
    • Combined with ritonavir, Lopinavir’s area under the curve (AUC) increases 14-fold (pharmacokinetic synergy) (ApexBio).
    • Lopinavir inhibits MERS-CoV, SARS-CoV, and HCoV-229E replication in cell culture with EC50 3–8 μM (Vero E6 cells, 48 h) (de Wilde et al., 2014).

    Applications, Limits & Misconceptions

    Lopinavir is widely used as a reference compound in HIV protease inhibition assays, resistance studies, and antiviral drug screening. Its robust serum stability and retained efficacy against key resistance mutations make it a benchmark for both fundamental and translational research [this article integrates broader cross-pathogen context and strategic guidance]. Recent studies have expanded its application to emerging viral pathogens, including coronaviruses, though primary clinical utility remains in HIV research.

    Common Pitfalls or Misconceptions

    • Misconception: Lopinavir is effective against all coronaviruses in vivo.
      Clarification: Its anti-coronavirus activity is demonstrated only in cell culture; efficacy in animal models or patients is unverified (de Wilde et al., 2014).
    • Pitfall: Assuming water solubility for in vitro work.
      Clarification: Lopinavir is insoluble in water; use DMSO (≥31.45 mg/mL) or ethanol (≥48.3 mg/mL) for preparation (ApexBio).
    • Misconception: Activity is unaffected by serum proteins.
      Clarification: While Lopinavir is less affected than ritonavir, some reduction in activity can still occur at high serum concentrations (ApexBio).
    • Pitfall: Long-term storage at room temperature preserves compound potency.
      Clarification: For optimal stability, prepare fresh solutions and store at -20°C (ApexBio).
    • Misconception: Lopinavir alone provides optimal plasma exposure in vivo.
      Clarification: Co-administration with ritonavir is required to achieve clinically relevant plasma levels due to pharmacokinetic synergy (ApexBio).

    Workflow Integration & Parameters

    For Lopinavir (SKU: A8204), prepare stock solutions in DMSO (≥31.45 mg/mL) or ethanol (≥48.3 mg/mL); do not use water. Store aliquots at -20°C to minimize degradation. For HIV protease inhibition assays, typical working concentrations range from 4–52 nM in cell-based formats (e.g., CEM or MT-2 cells, 72 h incubation, 37°C, 5% CO2). When exploring resistance, include Val82 and other common HIV protease mutants. For in vivo pharmacokinetics, oral administration is standard; expect Cmax of 0.8 μg/mL at 10 mg/kg. Combine with ritonavir to maximize systemic exposure. Always freshly prepare experimental solutions and verify concentration by HPLC or LC-MS. See the comprehensive guide for advanced troubleshooting and protocol optimization; this article extends those workflows with the latest resistance and pharmacology data.

    Conclusion & Outlook

    Lopinavir (ABT-378) remains a gold-standard HIV protease inhibitor, with robust performance against both wild-type and resistant HIV strains. Its favorable pharmacokinetics, serum stability, and cross-pathogen profile support its continued use in HIV research and antiretroviral development. Ongoing studies are evaluating broader antiviral applications, but current evidence supports its primary use as a reference and benchmark compound in HIV protease inhibition and resistance workflows. For ordering and technical details, refer to the A8204 Lopinavir product page.